Clinical Trial Update: A Study to Determine the Safety, Tolerability and Efficacy NW-3509A in Patients With Chronic Schizophrenia [Phase 2]

View source ↗

Summary

This clinical trial update notes the completion of a Phase 2 study evaluating NW-3509A for safety, tolerability, and efficacy in schizophrenia.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Schizophrenia

Drugs mentioned

• NW-3509A

Snippet

Sponsor: Newron Pharmaceuticals SPA | Conditions: Chronic Schizophrenia | Phase 2 | Status: COMPLETED